A Prospective, Open-label, Multi-center, Single Arm, Phase III Study of [68Ga]Ga-DOTA-TATE in the Diagnosis of Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use; Registrational
- Sponsors Novartis Pharmaceuticals
- 05 Mar 2025 Status changed from recruiting to completed.
- 02 Aug 2024 Planned End Date changed from 3 Jul 2025 to 31 Dec 2024.
- 02 Aug 2024 Planned primary completion date changed from 3 Jul 2025 to 31 Dec 2024.